Carregant...
Achieving Neuroprotection with LRRK2 kinase inhibitors in Parkinson Disease
In the translation of discoveries from the laboratory to the clinic, the track record in developing disease-modifying therapies in neurodegenerative disease is poor. A carefully designed development pipeline built from discoveries in both pre-clinical models and patient populations is necessary to o...
Guardat en:
| Publicat a: | Exp Neurol |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5693612/ https://ncbi.nlm.nih.gov/pubmed/28764903 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.expneurol.2017.07.019 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|